Page last updated: 2024-10-25

chlorpromazine and Dementias, Transmissible

chlorpromazine has been researched along with Dementias, Transmissible in 6 studies

Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamasaki, T1
Suzuki, A1
Hasebe, R1
Horiuchi, M1
Sasvari, Z1
Bach, S1
Blondel, M1
Nagy, PD1
Barret, A1
Tagliavini, F1
Forloni, G1
Bate, C1
Salmona, M1
Colombo, L1
De Luigi, A1
Limido, L1
Suardi, S1
Rossi, G1
Auvré, F1
Adjou, KT1
Salès, N1
Williams, A1
Lasmézas, C1
Deslys, JP1
Cronier, S1
Beringue, V1
Bellon, A1
Peyrin, JM1
Laude, H1
Korth, C1
May, BC1
Cohen, FE1
Prusiner, SB1
Love, R1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Novel Therapeutics For Prion Diseases: A Randomized, Double-blinded, Placebo-controlled Study of the Efficacy of Quinacrine in the Treatment of Sporadic Creutzfeldt-Jakob Disease[NCT00183092]Phase 269 participants (Actual)Interventional2005-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"Change in Phonemic Fluency (Words Beginning With Letter D)"

"Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (words beginning with letter D) is phonemic. Higher scores indicate better cognition." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-2.4
Quinacrine-2.2

ADAS-Cog Change After 2 Months Among Survivors

ADAS-cog measures cognitive performance by combining ratings of 11 components (word recall, word recognition, constructional praxis, orientation, naming objects and fingers, commands, ideational praxis, remembering instruction, spoken language, word finding, comprehension) representing six areas of cognition: memory; language; orientation to time, place and person; construction of simple designs and planning; and performing simple behaviors in pursuit of a basic, predefined goal. Seven components are scored as the 'number incorrect'. For example, in the commands component, the number of five commands performed incorrectly (range: 0-5). Four components are scored from 0 (no limitations) to 5 (max limitations) as the examiner's perception of remembering instructions, spoken language ability, word finding and comprehension. Component scores are summed into a total ADAS-cog score ranging from 0-75, with low scores indicating better cognitive performance. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo13.0
Quinacrine12.6

Barthel Score Change After 2 Months

An ordinal scale used to measure performance in activities of daily living. Scores range from 0 (worst, fully dependent) to 100 (best, independent); higher score associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital. 10 individual items are scored and summed to derive the overall Barthel index score. Each item may be scored 0, 5, 10 or 15; not all items use the full range of 4 possible values. The amount of time and physical assistance required to perform each item are considered in scoring each item. For subjects unable to return for month-2 visit, Barthel Index was performed via telephone. (NCT00183092)
Timeframe: baseline, 2 months

Interventionunits on a scale (Mean)
Placebo-23.2
Quinacrine-13.2

Change in Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB) After 2 Months

Clinical Dementia Rating Scale Sum of Boxes (CDRS-SB). The CDR is obtained through semistructured interviews of patients and informants, and cognitive functioning is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The global CDR score is computed via an algorithm. The CDR-SB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18. A higher value and/or positive change is worse. For subjects unable to return for month-2 visit, CDRS-SB was performed via telephone. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo3.2
Quinacrine0.3

Change in Mini-Mental State Examination (MMSE) After 2 Months

The mini-mental state examination (MMSE) is a brief 30-point questionnaire that is used to screen for cognitive impairment. In about 10 minutes it samples functions including arithmetic, memory and orientation. A score greater than or equal to 25 points (out of 30) indicates a normal cognition. Lower scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-24 points) cognitive impairment. Low to very low scores correlate closely with the presence of dementia, although other mental disorders can also lead to abnormal findings on MMSE testing. (NCT00183092)
Timeframe: Baseline to Month-2

Interventionunits on a scale (Mean)
Placebo-6.9
Quinacrine-3.9

Change in Rankin Score After 2 Months

"The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead. For subjects unable to return for the 2-month visit, Rankin score was assessed via telephone." (NCT00183092)
Timeframe: Baseline, 2 months

Interventionunits on a scale (Mean)
Placebo0.8
Quinacrine0.3

Change in Semantic Verbal Fluency (Naming Animals)

Verbal fluency tests are a kind of psychological test in which participants have to say as many words as possible from a category in 60 seconds. This category (naming animals) is semantic. Higher scores indicate better cognition. (NCT00183092)
Timeframe: Baseline, 2 months

Interventionnumber of words generated (Mean)
Placebo-3.2
Quinacrine-2.2

Primary Survival

Participants alive after 2 months on study treatment (NCT00183092)
Timeframe: Randomization to Month-2

Interventionparticipants (Number)
Placebo19
Quinacrine13

Other Studies

6 other studies available for chlorpromazine and Dementias, Transmissible

ArticleYear
Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Androstenes; Animals; Antibodies, Monoclonal, Murine-Derived; Cell Line, Tumor; Chlorpromazine; Endo

2014
Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities.
    PloS one, 2009, Oct-13, Volume: 4, Issue:10

    Topics: Acridines; Antiviral Agents; Chemistry, Pharmaceutical; Chlorpromazine; Drug Design; Models, Genetic

2009
Evaluation of quinacrine treatment for prion diseases.
    Journal of virology, 2003, Volume: 77, Issue:15

    Topics: Animals; Chlorpromazine; Cricetinae; Drug Resistance; Endopeptidase K; Humans; Melatonin; Mice; Mice

2003
Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures.
    Journal of virology, 2007, Volume: 81, Issue:24

    Topics: Amphotericin B; Animals; Cells, Cultured; Chlorpromazine; Congo Red; Cricetinae; Humans; Mice; Mice,

2007
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Aug-14, Volume: 98, Issue:17

    Topics: Acridines; Animals; Cells, Cultured; Chlorpromazine; Fatty Acids; Humans; Mice; Neuroblastoma; Pheno

2001
Old drugs to treat new variant Creutzfeldt-Jakob disease.
    Lancet (London, England), 2001, Aug-18, Volume: 358, Issue:9281

    Topics: Animals; Antimalarials; Antipsychotic Agents; Chlorpromazine; Creutzfeldt-Jakob Syndrome; Drug Thera

2001